Skip to content 
Asymmetrex
In the rapidly advancing field of regenerative medicine, one of the biggest challenges has been unlocking the full potential of adult stem cells—cells responsible for repairing and renewing human tissues. Asymmetrex is at the forefront of this scientific frontier, developing breakthrough technologies that aim to transform stem cell research, drug development, and clinical therapies.
Founded in 2013 by renowned scientist James L. Sherley, Asymmetrex builds on decades of pioneering research in stem cell biology. The company’s mission is clear: to overcome the two biggest barriers in stem cell medicine—accurate identification and scalable production of adult tissue stem cells—and bring these capabilities into mainstream medical practice.
At the core of Asymmetrex’s innovation is its ability to engineer and expand adult stem cells at scale. Through patented technologies such as SACK (Suppression of Asymmetric Cell Kinetics), the company aims to produce massive quantities of functional stem cells—potentially trillions at a time—while preserving their natural regenerative properties. This capability could revolutionize treatments for diseases where tissue repair is critical, including liver failure, diabetes, and degenerative conditions.
A defining breakthrough from Asymmetrex is its Kinetic Stem Cell (KSC) counting technology, which solves a decades-old problem in stem cell science: accurately measuring the number and quality of stem cells in a sample. Traditional methods often fail to distinguish true stem cells from similar progenitor cells, leading to unreliable results. Asymmetrex’s approach provides precise, differential counting—enabling better dosing, improved research outcomes, and safer therapies.
The company is also pushing boundaries with its AlphaSTEM technology, a computational simulation platform designed to estimate stem cell numbers and behavior across human tissues. This innovation has the potential to significantly reduce the time and cost of drug development by identifying toxic or ineffective drug candidates earlier in the process.
Unlike approaches that rely on embryonic or induced pluripotent stem cells, Asymmetrex focuses on adult tissue stem cells, which are naturally present in the body and less likely to cause mutations or tumor formation. This makes them particularly valuable for safe and effective regenerative therapies.
Beyond research, Asymmetrex is actively working toward commercial applications. Its technologies support pharmaceutical companies in drug testing, enable more effective stem cell therapies, and open doors to large-scale biomanufacturing of human cells. From liver cell production to future applications in skin, hair, and pancreatic therapies, the company is laying the groundwork for a new era of cellular medicine.
Another key strength is its intellectual property portfolio, which includes patented methods for stem cell production, identification, and evaluation. These innovations position Asymmetrex as a critical enabler in the broader biotechnology ecosystem, collaborating with research institutions and industry partners to accelerate progress.
In conclusion, Asymmetrex is not just advancing stem cell science—it is redefining it. By solving fundamental challenges in stem cell quantification and production, the company is paving the way for more effective therapies, faster drug discovery, and scalable regenerative solutions. As the demand for personalized and regenerative medicine grows, Asymmetrex stands as a visionary leader shaping the future of healthcare through adult stem cell engineering.
